Basic Information
| LncRNA/CircRNA Name | Erbb4-IR |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | qPCR etc |
| Sample | prostate carcinoma tissues, cell line(22Rv1, DU145) |
| Expression Pattern | down-regulated |
| Function Description | The results revealed that Erbb4-IR was downregulated in prostate carcinoma tissues compared with adjacent non-cancerous tissues, and that low expression of Erbb4-IR in tumor tissues was closely associated with poor survival. Furthermore, miR-21 was upregulated in prostate carcinoma tissues compared with adjacent non-cancerous tissues and was inversely associated with Erbb4-IR expression in tumor tissues. In vitro cell experiments revealed that Erbb4-IR overexpression resulted in the downregulation of miR-21, while miR-21 overexpression did not significantly affect the expression of Erbb4-IR. Moreover, Erbb4-IR overexpression increased apoptosis and inhibited the proliferation of prostate carcinoma cells. miR-21 overexpression resulted in the opposite effect and attenuated the effects of Erbb4-IR overexpression. Therefore, the results of the present study suggested that lncRNA Erbb4-IR is downregulated in prostate carcinoma and may inhibit cancer development by downregulating miR-21. |
| Pubmed ID | 32269615 |
| Year | 2020 |
| Title | lncRNA Erbb4-IR Is Downregulated in Prostate Carcinoma and Predicts Prognosis |
External Links
| Links for Erbb4-IR | GenBank HGNC NONCODE |
| Links for prostate cancer | OMIM COSMIC |